Compare HCI & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCI | VIR |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 773.5M |
| IPO Year | N/A | 2019 |
| Metric | HCI | VIR |
|---|---|---|
| Price | $186.10 | $6.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $230.00 | $25.73 |
| AVG Volume (30 Days) | 169.6K | ★ 1.8M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | ★ 32.29 | N/A |
| EPS | ★ 15.80 | N/A |
| Revenue | ★ $816,578,000.00 | $16,860,000.00 |
| Revenue This Year | $19.65 | N/A |
| Revenue Next Year | $9.97 | $48.05 |
| P/E Ratio | $11.86 | ★ N/A |
| Revenue Growth | ★ 8.75 | N/A |
| 52 Week Low | $106.89 | $4.16 |
| 52 Week High | $210.50 | $14.45 |
| Indicator | HCI | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 57.44 | 61.51 |
| Support Level | $171.99 | $6.49 |
| Resistance Level | $181.51 | $6.89 |
| Average True Range (ATR) | 5.23 | 0.47 |
| MACD | 1.54 | 0.06 |
| Stochastic Oscillator | 97.12 | 83.17 |
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.